secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prime Medicine, Inc. (PRME)
CIK:        0001894562
Form:       8-K
Filed at:   2023-08-07T23:59:59+00:00
Accession:  0001628280-23-027756
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prime Medicine Q2 net loss $42.4M; cash $221.1M; Cimeio partnership
-------------------------------------------------------------------

- Net loss of $42.4M for Q2 2023 vs $29.3M in Q2 2022; R&D expenses $34.6M (+83% YoY).
- Cash, equivalents and investments $221.1M as of June 30, 2023; runway into 2025.
- Entered research collaboration with Cimeio Therapeutics to develop shielded cell therapies for genetic diseases.
- PM359 for chronic granulomatous disease advancing; IND-enabling studies expected in 2023.
- First IND filing anticipated as early as 2024; additional filings in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1894562/000162828023027756/0001628280-23-027756-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1894562/000162828023027756/prme-20230807.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-027756

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer